Literature DB >> 3183851

Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin.

B Drumm1, P Sherman, D Chiasson, M Karmali, E Cutz.   

Abstract

We evaluated the efficacy of medical therapy, consisting of liquid bismuth subsalicylate prescribed either in combination with oral ampicillin (n = 15) or alone (n = 1), in the clearing of bacterial colonization on the antrum in 16 children with Campylobacter pylori-associated antral gastritis. We also examined the effects of medical treatment on altering the severity of associated antral inflammation. Eight patients had upper gastrointestinal tract hemorrhage, two had acute gastric outlet obstruction, and 10 had symptoms of episodic epigastric abdominal pain. Duodenal ulcers were demonstrated in 10 of the 16 patients; in the other six, C. pylori-associated antral gastritis was documented without evidence of acute peptic ulceration. Seven days after a 6-week course of medical therapy, repeat upper endoscopy plus mucosal biopsy specimens showed that C. pylori colonization of the antrum had cleared in 12 of the 16 (75%) patients. Inflammation in the antrum improved in all patients in whom colonization by C. pylori was eradicated. In contrast, in the four with persistent colonization of the antrum, the severity of antral gastritis had not improved (p less than 0.01). Clinical symptoms improved in 9 of 12 patients in whom C. pylori colonization was no longer present, whereas subjective symptoms were unaffected in those with continued bacterial colonization of the antrum (p less than 0.05). We conclude that oral bismuth subsalicylate, in conjunction with ampicillin, can eradicate C. pylori colonization of the antrum, and that clearing of C. pylori is correlated with an improvement in the associated antral gastritis and clinical symptoms. These findings provide additional support for the hypothesis that these gastric organisms could play an etiologic role in primary antral gastritis and peptic ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183851     DOI: 10.1016/s0022-3476(88)80030-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

Review 1.  Presentation and management of Helicobacter pylori infection in childhood.

Authors:  U Blecker; N K Mittal; D I Mehta
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

Review 2.  Helicobacter pylori infection and eradication in paediatric patients.

Authors:  H M Malaty
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

Review 3.  Helicobacter pylori.

Authors:  B Drumm
Journal:  Arch Dis Child       Date:  1990-11       Impact factor: 3.791

Review 4.  Helicobacter pylori eradication in patients with non-ulcer dyspepsia.

Authors:  H H Xia; N J Talley
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 5.  What do we know about benefits of H. pylori treatment in childhood?

Authors:  Mónica S Sierra; Emily V Hastings; Karen J Goodman
Journal:  Gut Microbes       Date:  2013-11-06

Review 6.  Helicobacter pylori disease in childhood.

Authors:  U Blecker
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

7.  Eradication of Helicobacter mustelae from the ferret stomach: an animal model of Helicobacter (Campylobacter) pylori chemotherapy.

Authors:  G Otto; J G Fox; P Y Wu; N S Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Helicobacter pylori and gastrointestinal symptoms.

Authors:  S Gormally; B Drumm
Journal:  Arch Dis Child       Date:  1994-03       Impact factor: 3.791

9.  Syncopes leading to the diagnosis of a Helicobacter pylori positive chronic active haemorrhagic gastritis.

Authors:  U Blecker; F Renders; S Lanciers; Y Vandenplas
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

10.  Treatment of Helicobacter pylori-associated gastroduodenal disease in children. Clinical evaluation of antisecretory vs antibacterial therapy.

Authors:  C Rosioru; M S Glassman; S H Berezin; H E Bostwick; M Halata; S M Schwarz
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.